Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.

We report the findings and outputs of an international expert opinion process to develop a definition of early Crohn's disease (CD) that could be used in future disease-modification trials. Nineteen experts on inflammatory bowel diseases held an international expert opinion meeting to discuss a...

Повний опис

Бібліографічні деталі
Автори:	Peyrin-Biroulet, L, Billioud, V, D'Haens, G, Panaccione, R, Feagan, B, Panés, J, Danese, S, Schreiber, S, Ogata, H, Hibi, T, Higgins, P, Beaugerie, L, Chowers, Y, Louis, E, Steinwurz, F, Reinisch, W, Rutgeerts, P, Colombel, J, Travis, S, Sandborn, W
Формат:	Journal article
Мова:	English
Опубліковано:	2012

Схожі ресурси

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
за авторством: Sandborn, W, та інші
Опубліковано: (2016)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
за авторством: Danese, S, та інші
Опубліковано: (2015)

Development of the Crohn's disease digestive damage score, the Lemann score.
за авторством: Pariente, B, та інші
Опубліковано: (2011)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
за авторством: Reinisch, W, та інші
Опубліковано: (2018)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
за авторством: D'Haens, G, та інші
Опубліковано: (2009)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
за авторством: Khanna, R, та інші
Опубліковано: (2023)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
за авторством: Colombel, J, та інші
Опубліковано: (2017)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
за авторством: Jairath, V, та інші
Опубліковано: (2016)

Evolving concepts in phases I and II drug development for Crohn's Disease
за авторством: Jairath, V, та інші
Опубліковано: (2016)

Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
за авторством: Laurent Peyrin-Biroulet, та інші
Опубліковано: (2024-01-01)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
за авторством: Remo Panaccione, та інші
Опубліковано: (2015-12-01)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
за авторством: Panaccione, R, та інші
Опубліковано: (2019)

Development of an index to define overall disease severity in IBD
за авторством: Siegel, C, та інші
Опубліковано: (2016)

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
за авторством: Peyrin-Biroulet, L, та інші
Опубліковано: (2015)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
за авторством: Gottlieb, K, та інші
Опубліковано: (2015)

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
за авторством: Yzet, C, та інші
Опубліковано: (2019)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
за авторством: Mahadevan, U, та інші
Опубліковано: (2011)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
за авторством: D'Haens, G, та інші
Опубліковано: (2018)

Management of Perianal Crohn's Disease
за авторством: Paul Rutgeerts
Опубліковано: (2000-01-01)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
за авторством: Gasche, C, та інші
Опубліковано: (2000)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
за авторством: D'Haens, G, та інші
Опубліковано: (2011)

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
за авторством: Travis, S, та інші
Опубліковано: (2006)

Infliximab in the Treatment of Crohn’s Disease
за авторством: Brian Feagan
Опубліковано: (2000-01-01)

Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.
за авторством: Ferrante, M, та інші
Опубліковано: (2012)

Taking Crohn’s Disease Personally
за авторством: Yehuda Chowers
Опубліковано: (2013-04-01)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
за авторством: Miquel Marquès Camí, та інші
Опубліковано: (2021-01-01)

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
за авторством: Clark, M, та інші
Опубліковано: (2007)

Can we change the natural course of inflammatory bowel disease?
за авторством: Catherine Le Berre, та інші
Опубліковано: (2023-04-01)

Steroid-Dependent Crohn’s Disease
за авторством: William J Sandborn
Опубліковано: (2000-01-01)

Closure of enterovesical fistula in Crohn’s disease with infliximab: case report
за авторством: Flávio Steinwurz
Опубліковано: (2003-03-01)

Estudo evolutivo de fístulas na doença de Crohn A follow-up study of fistulae in Crohn's disease
за авторством: Flavio STEINWURZ
Опубліковано: (1999-12-01)

Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease
за авторством: Brian G. Feagan, та інші
Опубліковано: (2025-01-01)

Risk Factors for Relapse and Recurrence of Ulcerative Colitis and Crohn’s Disease
за авторством: Paul Rutgeerts
Опубліковано: (1993-01-01)

Review article: defining remission in ulcerative colitis.
за авторством: Travis, S, та інші
Опубліковано: (2011)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
за авторством: Jairath, V, та інші
Опубліковано: (2016)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
за авторством: Van Assche, G, та інші
Опубліковано: (2011)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
за авторством: Laurent Peyrin‐Biroulet, та інші
Опубліковано: (2024-03-01)

Crohn’s Disease: We are in it for the Long Haul
за авторством: Remo Panaccione, та інші
Опубліковано: (2008-01-01)

Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.
за авторством: Sandborn, W, та інші
Опубліковано: (2001)

Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort studyResearch in context
за авторством: Mariangela Allocca, та інші
Опубліковано: (2024-05-01)